[Comment] A step towards antiepileptogenic therapies for post-stroke epilepsy

Seizures are a recognised complication of both ischaemic stroke and intracranial haemorrhage, and around 6% of patients develop post-stroke epilepsy, the leading cause of late-onset epilepsy.1 Although many patients with post-stroke epilepsy respond to antiseizure medication, a recent meta-analysis showed increased rates of long-term disability, recurrent stroke, dementia, and all-cause mortality in patients with post-stroke epilepsy compared with those without post-stroke epilepsy.2 Post-stroke epilepsy is thought to arise from insults disrupting local excitatory and inhibitory cortical activity, leading to hyperexcitability, with suggested roles for neuroinflammation and iron-mediated oxidative stress.